Neulasta and Bone marrow disorder - a phase IV clinical study of FDA data

Summary:

Bone marrow disorder is reported as a side effect among people who take Neulasta (pegfilgrastim), especially for people who are female, 40-49 old, have been taking the drug for < 1 month also take Cytoxan, and have Pain.

The phase IV clinical study analyzes which people have Bone marrow disorder when taking Neulasta. It is created by eHealthMe based on reports of 92,148 people who have side effects when taking Neulasta from the FDA, and is updated regularly.

What is Neulasta?

Neulasta has active ingredients of pegfilgrastim. It is often used in agranulocytosis. eHealthMe is studying from 92,286 Neulasta users. Check the latest studies of Neulasta.

What is Bone marrow disorder?

Bone marrow disorder is found to be associated with 413 drugs and 505 conditions by eHealthMe. Check the latest studies of Bone marrow disorder.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

92,148 people reported to have side effects when taking Neulasta.
Among them, 41 people (0.04%) have Bone marrow disorder.

Could Neulasta cause Bone marrow disorder?

Among these 41 people:

How long have people been on Neulasta when they have Bone marrow disorder? *

What is the gender of people who have Bone marrow disorder when taking Neulasta? *

female: 85 %
male: 15 %

What is the age of people who have Bone marrow disorder when taking Neulasta? *

What are other drugs people take besides Neulasta? *

What are other side effects people have besides Bone marrow disorder? *

Pain: 15 people, 36.59%
Depression: 13 people, 31.71%
Metastases To Liver (cancer spreads to liver): 12 people, 29.27%
Tooth Abscess (pus formation in tooth): 12 people, 29.27%
Anhedonia (inability to experience pleasure from activities usually found enjoyable): 12 people, 29.27%
Dental Caries: 12 people, 29.27%
Neuropathy Peripheral (surface nerve damage): 12 people, 29.27%
Spinal Osteoarthritis (joint cartilage loss in spine): 12 people, 29.27%
Stress And Anxiety: 12 people, 29.27%
Anaemia (lack of blood): 12 people, 29.27%

What are the existing conditions these people have? *

Pain: 10 people, 24.39%
Pain In Jaw: 9 people, 21.95%
Neoplasm Malignant (cancer tumour): 9 people, 21.95%
Depression: 9 people, 21.95%
Metastases To Bone (cancer spreads to bone): 3 people, 7.32%
Stress And Anxiety: 2 people, 4.88%
Wolff-Parkinson-White Syndrome (a heart condition in which there is an abnormal extra electrical pathway of the heart): 1 person, 2.44%
White Blood Cell Count Increased: 1 person, 2.44%
White Blood Cell Count Abnormal: 1 person, 2.44%
Renal Cell Carcinoma (a kidney cancer): 1 person, 2.44%

* Approximation only. Some reports may have incomplete information.

Do you take Neulasta and have Bone marrow disorder?

- Check whether Bone marrow disorder is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Neulasta:

Neulasta (92,286 reports)

Browse all side effects of Neulasta:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Bone marrow disorder:

Bone marrow disorder (413 drugs)

Browse all the conditions that are associated with Bone marrow disorder:

Bone marrow disorder (505 conditions)

Related publications that referenced our studies

Khan A, Yasin Z, "Hyperleukocytosis Caused By Neulasta Complicated By Leukostasis Versus Asymptomatic Uncomplicated Hyperleukocytosis In AML. Two Cases and When To Leukapherese.", Am Soc Hematology, 2017 Jan .
Khan A, Yasin Z, "Hyperleukocytosis Caused By Neulasta Complicated By Leukostasis Versus Asymptomatic Uncomplicated Hyperleukocytosis In AML. Two Cases and When To Leukapherese.", Am Soc Hematology, 2017 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on pegfilgrastim (the active ingredients of Neulasta) and Neulasta (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.